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indicating substantial agreement between the measures. 
 Conclusions: Our findings illustrate the difficulties in obtain-
ing valid information on prenatal cannabis use. To improve 
the quality of cannabis use data, we suggest a 2-step ap-
proach starting with self-report. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Cannabis is the most commonly used illicit substance 
in Western countries. In Europe, the 12-month preva-
lence of cannabis use among young adults increased from 
5% in 1990 to 15% in 2005  [1] . In young Australian wom-
en, the 12-month prevalence of cannabis use was 24.4% 
 [2] , and in young Canadian women it was 21.8%  [3] .
In pregnant women, the prevalence of cannabis use
was much lower, i.e. in 2007, 2.9% of Dutch women and 
1.8% of American women reported prenatal cannabis use 
 [4, 5] .
 In epidemiological studies, researchers often use dif-
ferent methods to assess substance use, such as biochem-
ical measures and self-report. Biochemical measures pro-
vide clear information on recent substance use, yet are 
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 Abstract 
 Aim: To verify self-reported information on prenatal drug 
use in urine because reporting in pregnancy is sensitive to 
stigma and might lead to misclassification.  Methods: Using 
semiquantitative immunochemical analysis, the presence of 
the urinary metabolite (11-nor-  9–tetrahydrocannabinol-
9-carboxylic acid) was compared to self-reported prenatal 
cannabis use. Sensitivity and specificity for self-report and 
urinalysis outcomes were calculated and Yule’s Y was used as 
an agreement measure.  Results: Urine samples were avail-
able for 3,997 pregnant women. Of these women, 92 report-
ed having used cannabis during pregnancy (2.3%) and 71 
had positive urine screens (1.8%). In total 35% of the 92 wom-
en with self-reported cannabis use also had a positive urine 
screen. Positive urines were relatively frequent in women re-
porting cannabis use before pregnancy only (7.6%) and in 
women with missing information (2.6%). Sensitivity and 
specificity of urinalysis compared to self-report were 0.46 
and 0.98. Sensitivity and specificity of self-report compared 
to urinalysis were 0.36 and 0.99. Yule’s Y amounted to 0.77, 
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restricted by error rates, brief detection time periods and 
high costs. Self-reports are less invasive and permit the 
evaluation of substance use over longer periods in time, 
but are influenced by possible reporter social desirability 
and forgetfulness. Although multiple studies on consis-
tency and validity of multiple assessment methods among 
adults and adolescents have been reported  [6] , little infor-
mation is available on the agreement between self-report-
ed cannabis use and urinalysis in pregnancy. Previous 
hospital-based research has demonstrated that self-re-
ported use correlates moderately with biochemical mea-
sures of exposure to cannabis  [7, 8] .
 In previous studies of a population-based cohort in the 
Netherlands, we based prenatal cannabis use on self-re-
ported information collected using a questionnaire in 
pregnancy  [4, 9] . Although self-report is a commonly 
used measure to assess substance use, it is acknowledged 
that individuals may underreport or deny substance use, 
especially during pregnancy  [10] . Cannabis use is not 
prosecuted in the Netherlands, and false negative report-
ing may therefore occur less frequently than in other 
countries; however, misclassification cannot be ruled out. 
Factors that may lead pregnant women to underreport 
substance use could be social desirability, forgetfulness, 
perceived norms about acceptability and fear of conse-
quences. Therefore, it is important to verify self-reported 
information on prenatal cannabis use by means of detect-
ing urinary cannabis metabolites. Moreover, we were 
particularly interested in exploring whether or not miss-
ing information on self-reported cannabis use was related 
to an increased risk of positive urine screens. In this 
study, the focus is on prenatal cannabis use exclusively, as 
in a general population-based cohort, the prevalence of 
other illicit drug use during pregnancy (e.g. cocaine, am-
phetamines) is expected to be very low. In addition, uri-
nary detection time of other substances is shorter (e.g. 
cocaine assesses 1–3 days) as compared to detection time 
of the cannabis metabolite, which has a long half-life in 
the body of up to several days or even weeks, depending 
on the frequency of use  [11–15] .
 In the current study, self-reported information on pre-
natal cannabis use was compared to the presence of the 
metabolite 11-nor-  9–tetrahydrocannabinol-9-carbox-
ylic acid (11-nor-  9-THC-9-COOH) using semiquanti-
tative immunochemical urinalysis. Although available 
data suggest that self-reported cannabis use correlates 
only moderately with biochemical measures, we hypoth-
esize substantial agreement between these measures in 
our cohort as cannabis use is not prosecuted in the Neth-
erlands  [16] .
 Methods 
 Study Population 
 This study was conducted within the Generation R study, a 
population-based birth cohort in Rotterdam, the Netherlands 
 [17] , set up to collect data on a sample of parents and their children 
from early pregnancy onwards. All children were born between 
April 2002 and January 2006 and constitute a prenatally enrolled 
birth cohort that is currently followed until young adulthood. In 
total 8,880 women (response rate 61%) were enrolled in Genera-
tion R during pregnancy. The study was conducted in accordance 
with the guidelines proposed in the World Medical Association 
Declaration of Helsinki, and it was approved by the Medical Eth-
ics Committee of the Erasmus Medical Centre, Rotterdam. Writ-
ten informed consent was obtained from all participants.
 Self-Reported Maternal Substance Use 
 Alcohol, tobacco and cannabis use were measured using a self-
report questionnaire at enrolment (usually in the 1st trimester of 
pregnancy; response rate for report on cannabis use was 85.7%). 
These questionnaires were handled anonymously by using bar-
codes instead of names and birthdates. We explicitly asked them 
to retrospectively reply to 2 separate questions of whether they 
had used these substances before pregnancy, and whether they 
had used them in the last 3 months. In the latter question the re-
sponse options were: ‘no’, ‘yes, until I knew I was pregnant’ and 
‘yes, I still use substances’. This information was therefore not 
specific for the entire gestational period. Mothers also provided 
information on the substance use of the biological father of the 
child. Based on these questions, we grouped the total population 
(n = 8,880) for this study in 4 nonoverlapping categories: (1) can-
nabis use before and during pregnancy (n = 220), (2) cannabis use 
before pregnancy only (n = 246), (3) missing information on can-
nabis use (n = 1,270) and (4) no cannabis use before or during 
pregnancy (n = 7,144). Self-reported numbers of cannabis use 
 before pregnancy (2.8%) and during pregnancy (2.5%) were in 
agreement with national numbers of cannabis use among Dutch 
women aged between 15 and 64 years (recent use: 3.1%; current 
use: 1.5%) in the same period  [18] . Substance use was unknown 
for 1,270 women of the total population (14.3%), which was due to 
failure to return the questionnaire (n = 764) or failure to fill out 
the specific question on substance use (n = 506).
 Urine Collection and Analysis 
 Details of biological specimen collection and storage have 
been described previously  [17] . Maternal urine samples were col-
lected in early, mid- and late pregnancy between February 2004 
and November 2005. From April to July 2008, about 14 batches 
(n = 300 per batch) of 3 ml of urine were sent to the Delta labora-
tory in Poortugaal, the Netherlands, and were tested on the pres-
ence of 11-nor-  9-THC-9-COOH using the DRI  Cannabinoid 
Assay (Microgenics) with a cutoff value of 50   g/l as recommend-
ed by the manufacturer and the Substance Abuse and Mental 
Health Security Agency. Using lower cutoff levels (20–40   g/l) 
resulted in similar values of agreement between urinalyses and 
self-reports. We therefore only reported the results using the rec-
ommended cutoff level of 50   g/l. For each urine sample, creati-
nine concentrations were determined, as this provides informa-
tion on possible urinary dilution (normal urine  6 1.8 mmol/l; di-
luted  ! 1.8 mmol; inconsistent with human urine  ^  0.4 mmol/l) 
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 [19, 20] . Of all samples, 5.6% (n = 222) were diluted, and based on 
the creatinine levels only 1 sample was deemed as inconsistent 
with human urine. Deleting or including these samples in the 
analyses did not change any of the results. Urine samples were 
missing in almost half of the cohort because urine sample collec-
tion was performed during a limited period in the prenatal phase 
of the study  [17] . For the current study, we could therefore use 
urine samples of 3,997 pregnant women. Due to this limited pe-
riod of urine collection, 78.9% (n = 2,375) of the pregnant women 
filled out the questionnaire after urine collection, and the re-
maining 21.1% filled out the questionnaire before urine sample 
collection.
 Data Analysis 
 First, we compared women with urine samples (n = 3,997) and 
women without urine samples (n = 4,883) on several characteris-
tics such as maternal age, ethnicity  [21] , educational level  [22] , 
maternal psychopathology  [23] and maternal report on alcohol, 
tobacco and cannabis use during pregnancy using independent t 
tests for continuous variables and a   2 test for categorical vari-
ables. The urinary average creatinine levels were compared using 
ANOVAs among the following groups: women reporting (1) can-
nabis use during pregnancy, (2) cannabis use before pregnancy, 
(3) no cannabis use and (4) women without information on can-
nabis use. Self-reported data on cannabis use and the presence of 
11-nor-  9-THC-9-COOH in maternal urine were compared us-
ing a 2  ! 2 contingency table. We calculated the sensitivity and 
specificity for urinalyses compared to self-report, and vice versa, 
because we did not consider either of the 2 measurements as the 
golden standard. 
 Additionally, Yule’s Y was calculated as a measure of overall 
agreement between self-reported cannabis use and urinalysis 
findings. Yule’s   , also called the coefficient of colligation for di-
chotomous variables, is exactly equivalent to Hoehler’s adjusted   
of agreement  [24] , but appears to be less dependent on prevalence 
than   . Yule’s   is a symmetric measure taking on values between 
–1 and +1 implying a perfect negative or positive association – 
0 implies no association. Yule’s Y is calculated using the 2  ! 2 
table with: Y = (  ad –   bc)/(  ad +   bc). Results were considered 
significant at p  ! 0.01. We chose this conservative significance 
level because given a sufficiently large sample, as we have in this 
study, extremely small and negligible differences can be found to 
be statistically significant. Statistical analyses were performed us-
ing the Statistical Package of Social Sciences version 15.0 for Win-
dows (SPSS Inc., Chicago, Ill., USA).
 Results 
 Attrition Analysis 
 The urine samples of 3,997 of 8,880 pregnant mothers 
were available ( table  1 ). Nonresponse analyses showed 
small differences between women with and without urine 
samples; women without urine samples were significant-
ly younger (0.5 years), somewhat lower educated (39.4% 
higher educated vs. 45.5%) and smoked slightly more of-
ten during pregnancy (25.7 vs. 22.2%) as compared to 
women with urine samples. No statistically significant 
differences in maternal and paternal cannabis use, ma-
ternal alcohol use and ethnicity were found.
 Self-Report and Urinalysis 
 Of 3,997 pregnant women, 92 reported having used 
cannabis during pregnancy (2.3%), while we found 71 
positive urine screens of all women whether they report-
ed cannabis use or not (1.8%). The numbers (92 self-re-
ports and 71 positive urine screens) were not completely 
overlapping ( table  2 ). Of the 92 mothers who reported 
having used cannabis during pregnancy, 33 mothers had 
Table 1.  Characteristics of mothers with and without urine sam-
ples
Mothers with
urine samples
(n = 3,997)
Mothers without
urine samples
(n = 4,883)
Effect
size
Maternal age 29.985.2 29.485.4* 0.10
Maternal education, %
Primary education 12.3 13.3* 0.06
Secondary education 42.3 47.3
Higher education 45.5 39.4
Marital status, %
Nonmarried 49.4 51.9 0.03
Maternal psychopathology
General Symptom Index 0.2980.38 0.3180.39 0.05
Maternal ethnicity, %
Dutch 48.2 50.3 0.02
Non-Dutch 51.8 49.4
Maternal tobacco use, %
None 61.3 56.9* 0.05
Before pregnancy 16.5 17.4
During pregnancy 22.2 25.7
Maternal alcohol use, %
None 33.1 32.5 0.02
Before pregnancy 24.8 24.5
During pregnancy 42.1 43.1
Maternal cannabis use, %
None 80.1 80.7 0.02
Before pregnancy 3.0 2.6
During pregnancy 2.3 2.6
Unknown 14.7 14.0
Paternal cannabis use, %
None 88.7 87.7 0.02
Yes 10.2 10.7
Unknown 1.2 1.6
Figures are mean 8 SD or percentages. S tatistical significance 
was derived from independent t tests for continuous variables and 
a 2 test for categorical variables (* p < 0.01). Effects sizes were 
calculated by Cohen’s d for continuous variables and phi was used 
for categorical variables.
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a positive urine screen. Based on these data, the total 
number of women with at least some evidence of canna-
bis use during pregnancy amounts to 92 (self-reported) + 
15 + 14 + 9 (positive urine tests without self-reported can-
nabis use) = 130, i.e. 3.3% of the group with urinalysis 
data ( table 2 , lower part). And, these data indicate that 92 
of the 130 women with probable cannabis use during 
pregnancy (70.7%) reported their cannabis use. In addi-
tion, based on a combination of positive self-report and 
positive urinalysis data, at least 130 of the 3,997 pregnant 
women used cannabis during pregnancy (3.3%), i.e. 1.43 
times the prevalence of cannabis use during pregnancy 
based on self-reported data only and 1.83 times the prev-
alence based on urinalysis data only.  Table 2 (lower part) 
demonstrates that a sizeable proportion of positive urine 
screens was found in women who reported cannabis use 
during pregnancy (35.9%), a substantial proportion of 
positive screens was found in women who reported can-
nabis use only before pregnancy (7.6%), a very small pro-
portion of positive screens was found in women who re-
ported no cannabis use (0.4%), and an intermediate pro-
portion of positive screens was found in women without 
self-report data on cannabis use (2.6%).
 Creatinine Levels 
 Average creatinine levels were not statistically differ-
ent across groups (F = 2.23, p = 0.082;  table 2 ). Moreover, 
no significant difference between mean maternal urinary 
creatinine levels in women who reported having used 
cannabis during pregnancy (9.4  8 5.5 mmol/l) and of 
mothers who reported not having used cannabis during 
pregnancy (8.4  8 5.4 mmol/l) was found (t = 1.78; p = 
0.074). Mean creatinine levels for cannabinoid-positive 
(n = 71,   = 12.5  8 7.0 mmol/l) and cannabinoid-nega-
tive urine samples (n = 3,926,   = 8.4  8 5.3 mmol/l) were 
significantly different (t = 6.41; p  ! 0.001).
 Sensitivity, Specificity and Yule’s Y 
 Sensitivity and specificity of the urinalysis as com-
pared to self-report were 33/71 = 0.46 and 3,867/3,926 = 
0.98, respectively. In addition, sensitivity and specificity 
of self-report as compared to urinalysis were 33/92 = 0.36 
and 3,867/3,905 = 0.99. These findings (based on  table 2 ) 
indicate that both approaches perform very well in the 
identification of noncannabis users, but that both mea-
sures seem to identify partially different subpopulations 
of cannabis users during pregnancy. Based on  table 2 , it 
was possible to calculate overall Yule’s Y: (  33  3,867 – 
  59  38)/(  33  3,867 +   59  38) = 0.77, indicating substantial 
agreement between the 2 measures. When calculated by 
comparing pregnant cannabis users and women who re-
ported nonuse (Group B 3 in  table 2 ), Yule’s Y was some-
what higher: (  33  3,187 –   59  14)/(  33  3,187 +   59  14) = 
0.84.
Table 2.  2 ! 2 contingency table for calculating sensitivity, specificity and Yule’s Y with absolute and relative numbers of available 
urine samples, positive detected urine screens and mean creatinine level
Maternal self-report U rinalysis
positive (%)a negative (%)a total (%)b creatinine in mmol/l
(mean 8 SD)
Cannabis use during pregnancy (Group A; n = 220) 33 (35.9) 59 (64.1) 92 (41.8) 9.485.5
All other women (Group B; n = 8,660) 38 (1.0) 3,867 (99.0) 3,905 (45.1) 8.485.4
Total (n = 8,880) 71 (1.8) 3,926 (98.2) 3,997 (45.0) 8.485.4
Cannabis use during pregnancy (Group A; n = 220) 33 (35.9) 59 (64.1) 92 (41.8) 9.485.5
Cannabis use before pregnancy (Group B1; n = 246) 9 (7.6) 109 (92.4) 118 (47.9) 8.684.2
Missing information (Group B2; n = 1,270) 15 (2.6) 571 (556) 586 (46.1) 8.885.0
No cannabis use during pregnancy (Group B3; n = 7,144) 14 (0.4) 3,187 (99.6) 3,201 (44.8) 8.485.5
Total (n = 8,880) 71 (1.8) 3,926 (98.2) 3,997 (45.0) 8.485.4
Gr oup B consists of 3 subgroups: B1, women reporting cannabis before pregnancy; B2, women without information on cannabis 
use; and B3, women reporting no cannabis use.
a Proportion of positive and negative urine screens based on the number of urine samples.
b Proportion of urine samples based on the total number of participants.
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 Paternal Cannabis Use 
 Additional analyses showed that, compared to women 
that reported not using cannabis, among pregnant wom-
en that reported cannabis use, paternal cannabis use was 
more common (78.9 vs. 8.5%; p  ! 0.001; phi = 0.38). More-
over, paternal cannabis use was also more common when 
maternal urine samples were positive (71.7 vs. 9.2%; p  ! 
0.001; phi = 0.26).
 Discussion 
 In this study, we compared self-reported information 
on prenatal maternal cannabis use with the presence of 
the cannabis metabolite, 11-nor-9-THC-9-COOH, mea-
sured by semiquantitative immunochemical urinalysis. 
Our findings demonstrated that reliance on urinalysis of 
a single urine specimen underestimates the prevalence of 
cannabis use during pregnancy profoundly and may be 
biased toward long-term or heavy users, as they are more 
likely than occasional users to be detected through uri-
nalysis. However, reliance on self-reported cannabis 
alone also underestimates the prevalence of prenatal can-
nabis use even in the Netherlands, where neither canna-
bis possession nor cannabis use is prosecuted.
 Our findings are to some extent in agreement with 
other studies. First, our findings are consistent with the 
report by Shiono et al. [7] that only 43.2% of the women 
reporting cannabis also had a positive serum assay result. 
However, our findings were not fully consistent with the 
data of Markovic et al. [8] , who reported much higher 
proportions of positive urine screens (86.6%) in women 
reporting current cannabis use in early pregnancy. A 
plausible explanation for this finding is that this sample 
was not representative of the general population, but was 
a selected group of 570 (out of 1,347) pregnant women 
with a high prevalence of cannabis use during pregnancy 
measured by self-report (16.8%) and urinalysis (21.5%) 
 [25] . Previous studies with different populations have re-
ported moderate agreement between self-reports on can-
nabis use and urinalysis  [6, 26] ; thus, we reported a high-
er agreement between self-report of cannabis use during 
pregnancy and urinalysis.
 Sensitivity, of both self-report and urinalysis, was 
moderate, whereas specificity of both assessment proce-
dures was high. If it can be assumed that false positive 
self-reports for cannabis use are unlikely, the negative 
urine screens of pregnant women reporting cannabis use 
during pregnancy are of interest. The main metabolite 
excreted in the urine (11-nor-  9-THC-9-COOH) is found 
within hours of exposure and remains detectable in the 
urine for 3–10 days after smoking a single dose. However, 
the length of time following cannabis use for a positive 
urine screen is dependent upon multiple factors, includ-
ing the frequency and amount of cannabis, metabolic 
rate, excretion rate, half-life time, storage of the urine 
samples and the cannabis-user’s age, body fat content, ac-
tivity and diet  [27, 28] . These difficulties may explain the 
finding of negative urine screens in 59 of the 92 women 
(64%) who reported cannabis use during pregnancy. A 
possible reason for this, and probably the main limitation 
of this study, is that we only took 1–3 urine samples per 
individual throughout pregnancy. Ideally, weekly urine 
sampling would provide better estimates and would pro-
vide information about newly used cannabis as well. So, 
in large epidemiological studies with limited numbers of 
urine samples, immunochemical urinalysis performed 
once per trimester cannot be regarded as the golden stan-
dard in assessing prenatal cannabis use. This may also 
mean that in the group of mothers who did not answer 
the question about substance use or reported nonuse, the 
true prevalence of cannabis use may be even higher. In 
fact, if the prevalence of prenatal cannabis use were esti-
mated based on the urinalysis findings, the fact that at 
least two thirds of cannabis-using women were not de-
tected in our study with urinalysis should be taken into 
account.
 In addition, some other limitations in this study should 
be considered. First, extended frozen storage may have 
possibly led to degradation of cannabinoids over time, 
and may have led to an underestimation of the prevalence 
of cannabinoids in urine. However, several studies have 
shown that change in concentrations of 11-nor-  9-THC-
9-COOH after long-term storage was not extensive 
( ! 15%)  [29, 30] . Second, we cannot rule out that women 
may wonder about specific aims for urine collection. We 
expected that knowing urine samples were collected 
(without a specific reason) did not influence cannabis use 
among these women. Third, exact information on the 
amount of time that had elapsed between filling out the 
questionnaire and urine collection was not available; 
however, in general women who visited the research cen-
ter for anthropometrics, ultrasound measurements and 
blood and urine collection filled out the questionnaire
at approximately the same time. Alternative detection 
methods such as hair examination is limited too, as can-
nabis incorporation depends on growth rate, anatomical 
region, age, gender, ethnicity, hair color and individual 
variability  [31] . One could consider testing cannabis by 
using meconium, but meconium testing has some limita-
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tions as well. First, meconium begins forming in the 12th 
week of gestation, so this theoretically means collecting 
endogenous and exogenous wastes from the 2nd trimes-
ter onwards  [32] . Therefore, in large populations with 
limited resources, the most sensible method is to use self-
reported information on prenatal drug exposure, as this 
is likely to provide the best estimate for the lowest price 
(highest cost effectiveness). Fourth, the nonresponse 
analysis showed small differences between women with 
and without urine samples, which may increase the like-
lihood for cannabis use in women without urine samples. 
However, we previously reported that paternal cannabis 
use is the main determinant for prenatal cannabis use  [4] , 
and in the current study, the additional analyses showed 
that paternal cannabis use occurs more often when moth-
ers report cannabis use during pregnancy or when can-
nabinoids are detected in urine samples. Therefore, it is 
essential to consider paternal cannabis use. Finally, a total 
of 61% of all eligible women participated in the Genera-
tion R study  [33] and they may not be completely repre-
sentative of the general Rotterdam population  [34] . This 
may perhaps have led to an unfavorable selection of non-
using women. Yet, this selection bias does not necessarily 
mean that the relationship between self-reported canna-
bis use and urinalysis presented in this study was dis-
torted.
 In conclusion, researchers and clinicians, should ac-
knowledge that pregnant women may underreport cur-
rent cannabis use, a situation that seems most prevalent 
in women admitting past cannabis use (i.e. cannabis use 
before the pregnancy) and in women refusing to pro-
vide information on prenatal cannabis use. Finally, our 
findings illustrate the difficulties in obtaining valid in-
formation on prenatal cannabis use. Nonetheless, self-
report seems to be an acceptable single method to de-
termine cannabis use during pregnancy in epidemio-
logical studies. Importantly, in order to improve the 
quality of cannabis use data, we suggest a 2-step ap-
proach starting with self-report information and fol-
lowed by urinalysis in women who reported cannabis 
use before pregnancy, refused to answer questions about 
substance use during pregnancy and have partners that 
use cannabis. 
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